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The  importance  of  vaccination  during  pregnancy  lies  not  only  in  directly  protecting  vaccinated  women,
but also  by  indirectly  protecting  small  infants  during  the  ﬁrst  few  months  of  life. Vaccination  against  the
ﬂu  and  whooping  cough  is  a  priority  within  the comprehensive  care  strategy  for  pregnant  women  and
small  infants  in  Argentina,  in  the  context  of transitioning  from  child  vaccination  to  family vaccination.
In 2011,  the  ﬂu  vaccine  was  included  in the  National  Immunization  Schedule  (NIS)  as mandatory  and
free of  charge,  with  the aim of decreasing  complications  and  death  due  to  inﬂuenza  in the  at-risk  pop-
ulation  in  Argentina.  The  national  vaccination  coverage  attained  in  pregnant  women  in the  past  4 years
(2011–2014)  has  been  satisfactory;  88%  coverage  was  attained  in  the  year  this  program  was  introduced
to  the  schedule.  In the  following  years,  coverage  was maintained  at greater  than  95%.  In  February  2012,
Argentina  became  the ﬁrst  country  in  Latin  America  to  have  universal  vaccination  strategy  for  pregnant
women  against  whooping  cough.  This  recommendation  was  implemented  throughout  the  country  by
vaccination  with  the  diphtheria  toxoid,  tetanus  toxoid,  and  acellular  pertussis  (Tdap)  vaccine  starting  at
20 weeks  of  pregnancy,  with  the  aim  of  decreasing  morbimortality  due  to  whooping  cough  in  infants
under  6  months  of  age.  The  vaccine  was incorporated  into  the  NIS  in 2014.  More  than  1,200,000  doses
were  applied  in  this  period.  Both  vaccines  showed  a suitable  safety  proﬁle  and  no  serious  events  were
reported.
Argentina  is  an  example  of  a middle-income  country  that has  been  able  to  implement  a  successful
strategy  for  primary  prevention  through  vaccines,  making  it a health  policy.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
The Republic of Argentina is part of the Region of the Americas.
ocated at the southeastern part of the American continent, its con-
inental surface is around 2,780,000 km2 and it extends 3800 km
rom north to south and 1425 km from east to west. The terri-
ory is quite diverse, including mountainous regions, plateaus, and
lains, with extensive climatic and cultural diversity. Organized as
 republican, representative, and federal system, it is composed of
4 jurisdictions: 23 provinces and one autonomous city. There are
ore than 40 million inhabitants [1] and more than 750,000 births
re reported each year [2].
∗ Corresponding author. Tel.: +54 1143427388.
E-mail addresses: sneyro@dinacei.msal.gov.ar, silvinaneyro@gmail.com
S. Neyro).
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.109
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
Argentina is a middle-income country in which the primary pre-
vention strategy, by way  of vaccines, was  established as a priority
in public health, comprising a policy of state in the last decade.
The health system is composed of three subsectors: public, pri-
vate, and social security. Nevertheless, all inhabitants in the country
are guaranteed universal and free access to health by means of
the public system and through the national government. The sys-
tem guarantees all vaccines included in the NIS, as overseen by the
Argentinean State at the more than 8000 public vaccination centers
located throughout the country.
The evolution and growth of the NIS in this period has made it
one of the most modern and comprehensive in the region [3], with
19 free and mandatory vaccines available universally for all stages
of life and in all sectors of the population. It is therefore a robust
indicator of social equity and inclusion.
This vision of public health prioritizes the strategy for primary
prevention through vaccines, which is reﬂected by the incorpora-
tion of 13 of the 19 vaccines as part of the schedule, and an over
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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7-fold increase in the national budget earmarked for vaccination
n the last decade.
One of the most important challenges in this period has been the
ransition from child vaccination to family vaccination, in which the
accination of pregnant women is a cornerstone. Part of the chal-
enge was the inclusion of the obstetricians and heath personnel
ho take care of pregnant women and the newborns as a part of the
trategy. The epidemiological circumstances faced before the start
f the strategy of maternal immunization, reﬂected in the mor-
ality of pregnant women with inﬂuenza during 2009–2010 and
oung infants during the outbreak of pertussis in 2011, aware heath
ersonnel and general population, attaching high strategy adhe-
ion. This allowed turning a potential threat into an opportunity
or reaching satisfactory vaccine coverages.
As pregnancy vaccination takes place at primary care facilities
hich belong to the Expanded Program on Immunization, and not
t the obstetrician ofﬁce, it is offered to all women even if they did
ot achieve the obstetrician recommendation.
The importance of vaccination during pregnancy lies not only in
irectly protecting vaccinated women, but also by indirectly pro-
ecting small infants during the ﬁrst few months of life. This is based
n passive immunization generated by the transplacental transfer
f maternal antibodies to infants who cannot be vaccinated due to
heir chronological age. Therefore, ﬂu and whooping cough vac-
ination is a priority within the comprehensive care strategy of
regnant women and small infants in Argentina.
Safety monitoring in vaccines is also a paramount objective in
rgentina. The notiﬁcation of adverse events following immuniza-
ion (AEFI) is performed passively. This implies that cases must
e spontaneously reported by health effectors. The ﬁnal evalua-
ion and classiﬁcation of serious AEFI is performed by the Comisión
acional de Seguridad en Vacunas (CoNaSeVa) [National Commis-
ion for Safety in Vaccines]. It is composed of external consultants
ho belong to national scientiﬁc societies such as the Argentine
ociety of Pediatrics, the Argentine Society of Infectious Diseases,
he Argentine Society for Pediatric Infectious Diseases, the national
egulatory agency – Administración Nacional de Medicamentos,
limentos y Tecnología Médica (ANMAT) – [National Administra-
ion of Drugs, Food and Medical Technology], the Pan American
ealth Organization (PAHO), and representatives of the Dirección
acional de Control de Enfermedades Inmunoprevenibles (DiNa-
EI) [National Immunization Program.
. Development
.1. Inﬂuenza
Pregnant women infected by the inﬂuenza virus present a
reater risk of serious progression, hospitalization, and death com-
ared to the rest of the healthy adult population. The product of
onception can also be affected, generating intrauterine growth
estriction, premature birth, fetal and/or neonatal death [4–7].
Flu vaccination in pregnant women has been shown to be safe
nd effective in providing protection not only to the woman, but
lso to the fetus and infant [8,9], through the passive transfer of
ntibodies through the placenta [10,11].
The available scientiﬁc evidence sustains the safety of ﬂu vac-
ination [12,13] as a preventative measure during pregnancy and
hows the cost-effectiveness of the strategy [14] in terms of ﬂu pre-
ention and its complications, both in pregnancy and in the product
f conception. The PAHO establishes pregnant women as a priority
roup among the population in whom ﬂu vaccination is aimed..1.1. Experience in Argentina
The analysis of 332 total deaths occurring in Argentina dur-
ng the inﬂuenza A (H1N1) pandemic in 2009 evidenced that 6%3 (2015) 6413–6419
(20/332) of the deaths occurred in pregnant women and women in
the immediate postpartum. Of these, only 47% presented a comor-
bidity that would determine a greater risk of complications due
to the ﬂu, unlike 70% of the non-pregnant women who  died [15];
this highlights the vulnerability generated by the condition of being
pregnant itself in infection by the ﬂu virus.
The high number of pregnant and post-partum women  who died
is consistent with international reports that identify pregnancy as
an independent risk factor for serious disease and death due to
inﬂuenza [7,15,16]. The increased vulnerability of this population,
demonstrated nationally and internationally [6,15], led to the sub-
sequent deﬁnition of a sustained preventative strategy, through
the implementation of a free and mandatory ﬂu vaccine for at-risk
groups, including pregnant women.
In 2010, the largest national ﬂu vaccination campaign in the his-
tory of our country was  carried out, with the objective of decreasing
mortality due to the inﬂuenza A (H1N1) virus; it included 12 mil-
lion adjuvant monovalent vaccine doses. This strategy was  aimed
at pregnant women in any trimester of pregnancy, postpartum
women, health personnel, children 6–59 months of age and people
aged 5–64 years with risk factors (heart, kidney and chronic respi-
ratory diseases, immunocompromised, diabetes, morbid obesity,
etc.), and people over 65 years of age [17]. Vaccination coverage in
pregnant women  that year reached 98.1% (total number of doses
applied: 444,397), with an average national coverage for all risk
groups of 93.4%. Eighty-ﬁve percent (85%) of the target popula-
tion was  vaccinated at least 14 days prior to the start of the winter
season. In 2010, there were no cases of death due to conﬁrmed
ﬂu based on real time or conventional chain polymerase reaction
(CPR), reported in patients belonging to the aforementioned risk
groups.
In 2011, under the framework of a comprehensive prevention
strategy in respiratory diseases, Argentina incorporated the ﬂu vac-
cine into the NIS, as free and mandatory for all vulnerable groups
(children aged 6–24 months, postpartum women, health person-
nel, people aged 2–64 years of age with risk factors, and people
over the age of 65), including pregnant women in any trimester of
pregnancy, with the objective of decreasing complications, hospi-
talizations, and deaths due to the inﬂuenza virus [3,18].
Since its incorporation as part of the NIS in 2011 and through
2014, 1,422,059 ﬂu vaccine doses have been given to pregnant
women. The ﬂu vaccines, overseen by the national Ministry of
Health in this time period and used in this population, were
Agrippal® S1 (in 2011 and 2012) and Viraﬂu® (in 2013 and 2014);
both are inactivated, trivalent vaccines without adjuvants.
The national vaccination coverage attained in this group in the
past 4 years (2011–2014) has been satisfactory. Eighty-eight per-
cent (88%) coverage was achieved in the year this program was
introduced to the schedule and in the following years, coverage
was maintained at greater than 95% [19] (Graph 1). National Immu-
nization Program estimates ﬂu vaccination coverages in pregnant
women based on a 50% cohort of live newborns as denominator.
During the 2011–2014 period, 10 AEFI were reported (rate:
0.7/100,000 doses applied [d.a.]), of which 4 were mild events
associated with the vaccine (rate: 0.28/100.000 d.a.) and 5 were
program errors (rate: 0.35/100,000 d.a.). One case of ascending
acute ﬂaccid paralysis was reported and classiﬁed as non-
conclusive due to the lack of complementary studies. No deaths
were recorded due to inﬂuenza in promptly vaccinated pregnant
women, nor were there any serious adverse events reported in
relation to vaccination (Table 1).2.2. Whooping Cough
Whooping cough is an acute contagious and infectious dis-
ease that is vaccine-preventable; it essentially compromises the
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Sraph 1. Flu and Tdap vaccination coverage in pregnant women. Years 2011–2014. A
rgentina.
espiratory airways. Although it affects all age groups, infants and
mall children have been shown to be the groups with the greatest
orbidity and mortality, which in turn generate high health costs
20].
Even when the disease tends to be not serious in adolescents and
oung adults, the epidemiological implications are relevant as they
ay  constitute the main source or reservoir of infection, especially
or infants under 6 months of age in whom the disease may  develop
ith greater severity [21–23].
In this context, in the last 40 years, several vaccination strate-
ies have been tested, developed, and implemented in Argentina
nd around the world, with an aim to decrease the incidence
f whooping cough in the pediatric population, thus decreasing
ts morbimortality in the most vulnerable population, deﬁned as
nfants under one year of age.
These strategies have included direct vaccination of the
ediatric population (primary series in infants, with successive
einforcements until school-age), reinforcement doses for adoles-
ents [24], vaccination of postpartum women and cocoon strategy
25,26], and vaccination of health personnel assisting children
nder 12 months, and those living with neonates that weigh under
500 g at birth [25,27]. Despite the efforts undertaken, none of these
trategies have been able to substantially impact the infant popu-
ation under 6 months of age, who are unprotected as they are not
ld enough to receive the primary three-dose series.
able 1
lu and Tdap vaccination coverage in pregnant women. Years 2011–2014. Argentina.
Vaccine Flu 
Year 2011 2012 2013 201
Doses applied to pregnant women 329,697 367,081 381,658 343
AEFI  reported in pregnant women 0 1 4 5 
AEFI  rate in pregnant womenb 0 0.27 1.05 1.4
AEFI  vaccine related 0 1 3 0 
AEFI  vaccine related rateb 0 0.27 0.78 0 
Program errors 0 0 0 5 
Program errors rateb 0 0 0 1.4
ource: DiNaCEI [National Immunization Program], National Ministry of Health, Argentin
a 2014 Preliminary data as of 27 February 2015.
b Rates calculated for each 100,000 doses applied.ina. Source: DiNaCEI [National Immunization Program], National Ministry of Health,
In 2011, the US Center for Disease Control’s (CDC) Advisory
Committee on Immunization Practices (ACIP) recommended the
implementation of a vaccination strategy with the Tdap vaccine in
pregnant women  after the twentieth week of pregnancy, based on
scientiﬁc evidence that it sustains protection transferred to small
infants through the transplacental transfer of antibodies [25].
2.2.1. Experience in Argentina
The pediatric vaccination schedule for whooping cough in
Argentina includes three doses (2, 4, and 6 months). The ﬁrst
reinforcing dose (15–18 months) [3] was  started in the year 1978;
a second reinforcing dose (school-age) was added in 1985 using
a vaccine entirely composed of whole-cell pertussis [28]. This has
resulted in a decrease in the disease, as has also been observed in
other parts of the world [29].
While Argentinean national immunization program use whole
cell pertussis for children immunization, private subsector which
represents less than 5% of population provides both, cellular an
acellular pertussis vaccines.
Nevertheless, epidemiological monitoring of whooping cough
in Argentina has shown a growing trend in case reports in recent
years, which is consistent with reports by other countries with high
levels of vaccination coverage against pertussis [30–36] (Graph
2). The reasons for this increase are multifactorial: the high inci-
dence probably made the epidemiological monitoring system more
Tdap
4a Total 2012 2013 2014a Total
,623 1,422,059 372,242 470,352 416,129 1,258,723
10 7 8 5 20
5 0.7 1.88 1.7 1.2 1.59
4 3 2 2 7
0.28 0.81 0.43 0.48 0.57
5 4 5 3 12
5 0.35 1.07 1.06 0.72 0.95
a.
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ensitive, there have been advances in terms of the availability
f new diagnostic methods, case deﬁnitions have been modiﬁed
nabling stratiﬁcation by age group (given the differential presen-
ation of the disease in each group), etc.
This increase in case reports and deaths due to whooping
ough has been recorded since 2002; by 2011, the largest num-
er of deaths due to whooping cough had been recorded in recent
ecades. By speciﬁcally evaluating the deaths in 2011, a total of 76
ases were reported. Of these, 97.3% (74/76) were under one year
f age and 60.5% of them were under 2 months of age [37]. This
ituation generated the need to propose a prevention strategy for
hose infants who are too young to be vaccinated (Graph 3).
In 2011, the DiNaCEI [National Immunization Program] of the
ational Ministry of Health assembled the Comisión Nacional de
nmunizaciones (CoNaIn) [National Commission for Immuniza-
ions], a technical advisory group on vaccines in Argentina [38],
o agree upon a proposal given the emerging epidemiological situ-
tion in the country.
In this context, the need to establish a vaccination strategy
gainst whooping cough in pregnant women was proposed based
n the analysis of the national and international scientiﬁc evidence
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raph 3. Whooping cough, mortality by age group. Year 2011. Argentina. Source:
iNaCEI [National Immunization Program], National Ministry of Health, Argentina.rgentina. Source: DiNaCEI [National Immunization Program], National Ministry of
available at the time. This evidence showed low levels of anti-
Bordetella pertussis antibodies in postpartum women  who were not
vaccinated during pregnancy as well as low umbilical cord levels
[39]. Moreover, there was a greater possibility for transplacental
transfer of antibodies to infants in those women  who were vacci-
nated with Tdap during pregnancy. This hypothesis was sustained
by demonstrating a signiﬁcant increase in antibodies to pertussis
toxin and ﬁmbriae 2/3 in the children of mothers vaccinated with
Tdap during pregnancy, thus providing passive protection to small
infants [40–42].
In February 2012, Argentina became the ﬁrst country in Latin
America to have a universal vaccination strategy for pregnant
women against whooping cough. This recommendation was  imple-
mented throughout the country by free vaccination starting at 20
weeks of pregnancy, with an objective to decrease morbimortality
due to whooping cough in infants under 6 months of age.
In the year this strategy was started, national coverage for Tdap
vaccination in pregnant women reached 51%; by 2013, coverage
was greater than 67% (total number of doses applied: 470,352).
Preliminary data for vaccination coverage in 2014 show results that
reach 56.9% (Graph 1). National Immunization Program estimates
Tdap vaccination coverages in pregnant women based on a cohort
of live newborns as denominator.
The epidemiological situation was analyzed after this strategy
was implemented, ﬁnding an 87% decrease in absolute mortal-
ity. There was  a 69.9% decrease in the overall fatality rate (95%
conﬁdence interval [CI] = 50.38–81.81%; p < 0.001) and an 83.67%
decrease in infants under 2 months of age (95% CI = 63.92–92.61%;
p < 0.001) between 2011 and 2013. Of the deaths during this period,
89.8% (106/118) were under 6 months of age; of the 104 children
with anti-pertussis vaccination data, only 3 had completed three
vaccine doses (complete basic schedule)[43] (Graph 4). In 2014,
the lowest number of deaths due to whooping cough in the last 40
years (n = 6) was  registered, representing a 92% reduction compared
to 2011 (Graph 5).The evaluation of this strategy, 2 years after its recommendation
and implementation (2012–2013), led it to be incorporated into
the NIS in 2014 as free and mandatory for all pregnant residents
in the country [3,44], having demonstrated a signiﬁcant decrease
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Since this strategy was started in 2012, 1,258,723 total doses of
he Tdap vaccine have been administered to pregnant women. The
dap vaccines provided by the Ministry of Health in this period and
sed for the pregnant population alternated between Boostrix®
nd Adacel®.
A total of 20 AEFI were reported in the 2012–2014 period (rate:
.59/100,000 d.a.). Of these, 7 were mild and related to the vac-
ine (2 episodes of rash after vaccination and 5 local reactions with
ocal pain, redness and swelling). Sixty percent (60%) corresponded
o program errors (n = 12; rate: 0.95/100,000 d.a.). These were
ainly episodes in which the vaccine was administered before the
ecommended gestational age (20 weeks pregnant) and pregnant
omen were revaccinated with Tdap (strategy not recommended
n the country during the period analyzed). None of them presented
ubsequent complications. There were no serious or fatal events
eported (Table 1).
. ConclusionsArgentina is an example of a middle-income country that has
een able to implement a successful strategy for primary preven-
ion through vaccines, making it a health policy. To attain thisurce: Ofﬁce of Statics and Health Information and Jurisdiction Reports.
objective, a joint effort between health teams is key, from the
operational level to the central level, as is the support of scientiﬁc
societies and opinion leaders, the commitment of communication
media, and community awareness in terms of requesting the right
to vaccination.
Argentina was able to expedite a vaccination policy in pregnant
women, attaining satisfactory coverage in the vaccines prioritized
during this stage of life. Both vaccines are now included in the NIS,
ﬁnanced entirely by the national government.
In Argentina, vaccination in pregnant women is a sustained
strategy, with high coverage. This is the ﬁrst national study to show
the data regarding the safety of the ﬂu vaccine since it was  incor-
porated into the NIS. To our knowledge, it is also the ﬁrst report in
the Region of the Americas with safety data for the Tdap vaccine
administered to pregnant women. Both vaccines presented a suit-
able safety proﬁle. No serious adverse effects have been reported
since the strategy was implemented as free and mandatory.
Data obtained to date for the ﬂu and Tdap vaccines are promising
and are based on the continuity of a successful vaccination strategy
during pregnancy in Argentina.
Our primary concern is to share the Argentina experience in
order to encourage other countries with similar social, economic,
and cultural characteristics to call upon all the necessary play-
ers to undertake the challenge of prioritizing vaccination during
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